scispace - formally typeset
M

Mayte Pérez-Olmeda

Researcher at Carlos III Health Institute

Publications -  83
Citations -  4771

Mayte Pérez-Olmeda is an academic researcher from Carlos III Health Institute. The author has contributed to research in topics: Medicine & Population. The author has an hindex of 23, co-authored 67 publications receiving 3448 citations.

Papers
More filters
Journal ArticleDOI

Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study.

Marina Pollán, +95 more
- 22 Aug 2020 - 
TL;DR: In this paper, a nationwide population-based study aims to estimate the seroprevalence of SARS-CoV-2 infection in Spain at national and regional level.

Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study

Marina Pollán, +17 more
TL;DR: The majority of the Spanish population is seronegative to SARS-CoV-2 infection, even in hotspot areas, and results emphasise the need for maintaining public health measures to avoid a new epidemic wave.
Journal ArticleDOI

Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs

Mayte Coiras, +3 more
- 01 Nov 2009 - 
TL;DR: This Review analyses the molecular mechanisms that are necessary for the establishment of HIV-1 latency and their relationships with different cellular and anatomical reservoirs, and discusses the current treatment strategies for targeting viral persistence in reservoirs, their main limitations and future perspectives.
Journal ArticleDOI

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial.

Alberto M. Borobia, +160 more
- 10 Jul 2021 - 
TL;DR: In this paper, the authors assessed the immunogenicity and reactogenicity of BNT162b2 (Comirnaty, BioNTech, Mainz, Germany) administered as second dose in participants primed with ChAdOx1-S (Vaxzevria, AstraZeneca, Oxford, UK).
Journal ArticleDOI

Pegylated Ifn-α2b plus ribavirin as therapy for chronic hepatitis C in Hiv-infected patients

Mayte Pérez-Olmeda, +11 more
- 02 May 2003 - 
TL;DR: Treatment with peg-IFN and ribavirin is relatively well-tolerated in HIV/HCV-co-infected patients, although new side-effects, including pancreatitis and severe weight loss, may result from the interaction of ribvirin with antiretroviral drugs.